Chronic atrophic gastritis
Conditions
Interventions
Research Plan One (Western Medicine Group):Mosapride Citrate Tablets + Yaya Xiaozhang Granules Placebo
Research Plan Two (Yaya Xiaozhang Granules Group):Yaya Xiaozhang Granules+weisu Granules Placebo
Research Plan One (Yaya Xiaozhang Granules Group):Yaya Xiaozhang Granules+Morphine Citrate Tablets Simulator
Research Protocol 2 (weisu Granule Group):weisu Granules + Yaya Xiaozhang Granules Placebo
Sponsors
Shanghai Seventh People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) It meets the Western medical diagnostic criteria for CAG Patients with gastroscopy reports and pathological reports within one year and diagnosed with CAG can also be included in the group. 2) It meets the TCM diagnostic criteria for liver and stomach disharmony type CAG The subjects are aged 18 to 75 years old with no gender restrictions 4) The patient himself/herself and his/her family agreed to participate in this study and signed the informed consent form
Exclusion criteria
Exclusion criteria: 1) It does not meet the diagnostic criteria and inclusion criteria of both traditional Chinese and Western medicine for CAG 2) The patient is currently positive for Helicobacter pylori The age of the subjects should be under 18 years old or over 75 years old 4) Those who have taken drugs with similar components to those in this study within one month 5) Those with concurrent gastric ulcers severe dysplasia of the gastric mucosa or suspected malignant transformation as diagnosed by pathology 6) Those with severe cardiovascular respiratory system malignant tumor diseases and liver or kidney function damage or those suffering from organic diseases that seriously affect life and health safety 7) Women who are pregnant or breastfeeding 8) Patients with mental disorders (such as schizophrenia depression anxiety disorders etc.) 9) Those who have a severe allergic constitution or are allergic to the known drug components in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy index (effective rate);Overall improvement in gastric endoscopy findings;Efficacy index (effective rate); | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight and BMI;Pathological active inflammation;Gastrin 17;propepsin ?;FFQ25;Pepsinogen ratio(PG I/PG II);Pathological chronic inflammation;SF-36 Quality of Life Scale;Pepsinogen I; | — |
Countries
China
Contacts
Public ContactHu Dan
Shanghai Seventh People's Hospital
Outcome results
None listed